52-year-old man with steatosis and mild ALT elevation
A 52-year-old man with obesity, hypertension, and type 2 diabetes is seen for routine follow-up. He does not drink alcohol and takes metformin and lisinopril. He feels well. Laboratory studies show AST 42 U/L, ALT 56 U/L, platelet count 165,000/microL, albumin 4.2 g/dL, and total bilirubin 0.8 mg/dL. Hepatitis B surface antigen and hepatitis C antibody are negative. Abdominal ultrasound done for mildly abnormal liver tests shows diffuse hepatic steatosis without focal lesions. His calculated FIB-4 score is 1.1. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
C
Explanation
Clinical Pearl:
In suspected MASLD, the first step is fibrosis risk stratification rather than biopsy or drug therapy for everyone. Patients with low-risk noninvasive fibrosis scores can usually be managed in primary care with weight loss and treatment of metabolic comorbidities, with reassessment over time.
Explanation:
This patient has metabolic risk factors, hepatic steatosis on imaging, mild aminotransferase elevation, and no evidence of viral hepatitis or alcohol-related disease, making MASLD most likely. The key management question is fibrosis risk, and a low FIB-4 score identifies a patient at low likelihood of advanced fibrosis who should be managed with lifestyle-based weight reduction and aggressive treatment of diabetes, blood pressure, and other cardiovascular risk factors. Liver biopsy is not the best next step because it is reserved for diagnostic uncertainty or higher-risk patients after noninvasive assessment. Vitamin E is not first-line for a broadly asymptomatic patient with low fibrosis risk, and its use is selective rather than routine. Pioglitazone can help some patients with biopsy-proven steatohepatitis, especially with diabetes, but steatosis alone on ultrasound is not enough reason to start it solely for liver disease. Hepatocellular carcinoma surveillance is recommended for cirrhosis and certain high-risk chronic liver diseases, not for uncomplicated low-risk MASLD without advanced fibrosis.
See you tomorrow morning!